<ul>
<li>2026 年前你会后悔没有买的 3 只股票</li>
</ul>
<p>Celcuity, Inc.（纳斯达克代码：CELC - 免费报告）- HC Wainwright 的投资分析师在 6 月 3 日星期三向投资者发布的研究报告中下调了 Celcuity 的 2026 年第三季度每股收益（EPS）预期。HC Wainwright 的分析师 S. Ramakanth 现在预计该公司本季度每股收益为（$1.17），低于之前的预期（$1.16）。HC Wainwright 目前对该股票的评级为 “买入”，目标价为 145.00 美元。市场普遍预计 Celcuity 当前全年的每股收益为（$3.61）。HC Wainwright 还对 Celcuity 的 2026 年第四季度每股收益预期为（$0.64），2026 财年的每股收益预期为（$3.90），2027 财年的每股收益预期为（$0.56），2028 财年的每股收益预期为$3.14，2029 财年的每股收益预期为$6.16，以及 2030 财年的每股收益预期为$9.94。</p>
<p>Celcuity（纳斯达克代码：CELC - 获取免费报告）最近在 5 月 14 日星期四发布了其财报。该公司报告本季度每股收益为（$0.97），超出市场普遍预期的（$1.07）0.10 美元。</p>
<p>其他一些股票分析师也对该股票发表了看法。Stifel Nicolaus 在 5 月 4 日星期一的报告中对 Celcuity 的股票设定了 150.00 美元的目标价。Guggenheim 在星期三的报告中重申了对 Celcuity 股票的 “买入” 评级。Macquarie Infrastructure 在 5 月 28 日星期四的报告中对 Celcuity 的股票设定了 160.00 美元的目标价。Leerink Partners 在星期二设定了 155.00 美元的目标价。最后，Citizens Jmp 在 5 月 4 日星期一将 Celcuity 的目标价从 150.00 美元提升至 160.00 美元，并给予该股票 “市场表现优于大盘” 的评级。共有 11 位投资分析师对该股票给予了 “买入” 评级，1 位分析师对该公司的股票给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，目标价共识为 152.09 美元。</p>
<p><strong>查看我们最新的 Celcuity 股票分析</strong></p>
<h2>Celcuity 价格表现</h2>
<p>CELC 股票在星期五开盘价为 92.47 美元。该公司的 50 日移动平均价格为 122.45 美元，200 日移动平均价格为 111.55 美元。Celcuity 的 52 周低点为 11.27 美元，52 周高点为 151.02 美元。该公司的市值为 45.1 亿美元，市盈率为-23.71，贝塔值为 0.10。该公司的债务与股本比率为 6.04，速动比率为 12.31，流动比率为 12.31。</p>
<h2>机构投资者对 Celcuity 的看法</h2>
<p>对该股票的对冲基金最近增加或减少了其持股。Vanguard Group Inc.在第三季度将其在 Celcuity 的持股增加了 23.5%。Vanguard Group Inc.现在拥有 2,059,047 股该公司的股票，价值 101,717,000 美元，此前在上个季度又购买了 391,262 股。纽约州共同退休基金在第三季度将其在 Celcuity 的持股增加了 68.0%。纽约州共同退休基金现在拥有 47,704 股该公司的股票，价值 2,357,000 美元，此前在此期间又收购了 19,313 股。Candriam S.C.A.在第三季度将其在 Celcuity 的持股增加了 48.3%。Candriam S.C.A.现在拥有 390,924 股该公司的股票，价值 19,312,000 美元，此前在此期间又收购了 127,348 股。Choreo LLC 在第三季度购买了 Celcuity 的新股份，价值 248,000 美元。最后，TD Asset Management Inc 在第三季度购买了 Celcuity 的新股份，价值 3,596,000 美元。目前 63.33% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>内部人士下注</h2>
<p>在其他 Celcuity 的新闻中，董事 Richard E. Buller 在 5 月 4 日星期一出售了 9,000 股该公司的股票。该股票以平均价格 140.46 美元出售，总交易额为 1,264,140.00 美元。出售完成后，该董事直接持有该公司 6,760 股股票，价值约 949,509.60 美元。此次交易使其持股减少了 57.11%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 David Dalvey 在 5 月 4 日星期一出售了 25,000 股该公司的股票。该股票以平均价格 140.68 美元出售，总交易额为 3,517,000.00 美元。出售后，该董事持有 65,000 股该公司的股票，价值约 9,144,200 美元。这代表其持股减少了 27.78%。此次出售的披露信息可在 SEC 备案中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在上个季度，内部人士共出售了 37,000 股公司股票，价值 5,111,950 美元。公司内部人士持有公司股票的 13.33%。</p>
<h2>影响 Celcuity 的关键故事</h2>
<p>以下是本周影响 Celcuity 的关键新闻故事：</p>
<ul>
<li>积极情绪：HC Wainwright 对 Celcuity 维持 <strong>买入</strong> 评级，并重申 <strong>145 美元的目标价</strong>，显示出分析师对公司长期前景的持续信心。HC Wainwright 评级更新</li>
<li>积极情绪：Celcuity 表示正在 <strong>扩大第三阶段 VIKTORIA-2 试验</strong>，包括 <strong>内分泌敏感型乳腺癌患者</strong>，这可能会拓宽该药物的潜在市场并改善该项目的商业机会。VIKTORIA-2 试验扩展</li>
<li>积极情绪：多份报告强调了 gedatolisib 的 <strong>强劲第三阶段乳腺癌数据</strong>，评论员称这些结果可能是 <strong>改变实践的</strong>，并支持未来的 FDA 申请。强劲的第三阶段数据文章</li>
<li>中性情绪：HC Wainwright 更新了 2027 财年的盈利预测，包括后期季度的盈利能力预期，但这些修订主要是关于长期建模，而不是立即的商业事件。分析师估计更新</li>
<li>消极情绪：Celcuity 定价了一项 <strong>增大至 5 亿美元的可转换高级票据发行</strong>，到期时间为 2032 年，较最初计划的 4 亿美元有所增加，这引发了股东对 <strong>稀释和资产负债表的担忧</strong>。可转换票据定价</li>
<li>消极情绪：投资者对 <strong>ASCO26 试验失望</strong> 的反应也很强烈，报道指出，Celcuity 在最新数据未能完全满足市场预期后遭到 “惩罚”。ASCO26 失望</li>
</ul>
<h2>Celcuity 公司简介</h2>
<p>(获取免费报告)</p>
<p>Celcuity, Inc 是一家临床阶段的生物技术公司，专注于精准肿瘤学诊断。该公司开发和商业化预测性生物标志物检测，旨在识别哪些患者最有可能从靶向癌症疗法中受益。通过将肿瘤细胞的功能性分析与分子分析相结合，Celcuity 力求优化治疗选择并改善实体肿瘤患者的治疗效果。</p>
<p>Celcuity 的专有平台使用外源性检测评估肿瘤细胞对各种治疗药物的敏感性，测量 DNA 损伤反应和其他关键通路。</p>
<h2>精选文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Celcuity</li>
<li>买入下跌？博通的 AI 护城河比以往更宽</li>
<li>巨大的 AI 服务器轮换将惠普企业和超微计算机置于焦点</li>
<li>Generac 的 AI 动力转型引发了关于数据中心需求的更大问题</li>
<li>美敦力触底，健康反弹在前</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Celcuity 吗？</h2>
<p>在你考虑 Celcuity 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Celcuity 并不在名单上。</p>
<p>虽然 Celcuity 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得投资。</p>
<p>查看这五只股票</p>

CELC

<p>HC Wainwright 将 Celcuity (NASDAQ:CELC) 2026 年第三季度每股收益预期从 ($1.16) 下调至 ($1.17)，维持 “买入” 评级，目标价为 145 美元。尽管下调了预期，其他分析师如 Stifel、Guggenheim 和 Macquarie 仍然保持乐观，目标价在 150 至 160 美元之间。包括先锋集团在内的机构投资者增加了持股，而内部人士 Richard Buller 和 David Dalvey 在 五月份出售了股份</p>

<ul>
<li>3 Stocks You’ll Wish You Bought Before 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>2026 年前你会后悔没有买的 3 只股票</li>
</ul>
</div><p>Celcuity, Inc. (NASDAQ:CELC - Free Report) - Investment analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Celcuity in a research note issued to investors on Wednesday, June 3rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($1.17) for the quarter, down from their previous estimate of ($1.16). HC Wainwright currently has a &#34;Buy&#34; rating and a $145.00 target price on the stock. The consensus estimate for Celcuity's current full-year earnings is ($3.61) per share. HC Wainwright also issued estimates for Celcuity's Q4 2026 earnings at ($0.64) EPS, FY2026 earnings at ($3.90) EPS, FY2027 earnings at ($0.56) EPS, FY2028 earnings at $3.14 EPS, FY2029 earnings at $6.16 EPS and FY2030 earnings at $9.94 EPS.</p>
<div class="lb-trans"><p>Celcuity, Inc.（纳斯达克代码：CELC - 免费报告）- HC Wainwright 的投资分析师在 6 月 3 日星期三向投资者发布的研究报告中下调了 Celcuity 的 2026 年第三季度每股收益（EPS）预期。HC Wainwright 的分析师 S. Ramakanth 现在预计该公司本季度每股收益为（$1.17），低于之前的预期（$1.16）。HC Wainwright 目前对该股票的评级为 “买入”，目标价为 145.00 美元。市场普遍预计 Celcuity 当前全年的每股收益为（$3.61）。HC Wainwright 还对 Celcuity 的 2026 年第四季度每股收益预期为（$0.64），2026 财年的每股收益预期为（$3.90），2027 财年的每股收益预期为（$0.56），2028 财年的每股收益预期为$3.14，2029 财年的每股收益预期为$6.16，以及 2030 财年的每股收益预期为$9.94。</p>
</div><p>Celcuity (NASDAQ:CELC - Get Free Report) last released its earnings results on Thursday, May 14th. The company reported ($0.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.07) by $0.10.</p>
<div class="lb-trans"><p>Celcuity（纳斯达克代码：CELC - 获取免费报告）最近在 5 月 14 日星期四发布了其财报。该公司报告本季度每股收益为（$0.97），超出市场普遍预期的（$1.07）0.10 美元。</p>
</div><p>A number of other equities analysts have also weighed in on the stock. Stifel Nicolaus set a $150.00 price objective on shares of Celcuity in a report on Monday, May 4th. Guggenheim restated a &#34;buy&#34; rating on shares of Celcuity in a report on Wednesday. Macquarie Infrastructure set a $160.00 price objective on shares of Celcuity in a report on Thursday, May 28th. Leerink Partners set a $155.00 price objective on shares of Celcuity in a report on Tuesday. Finally, Citizens Jmp boosted their price objective on shares of Celcuity from $150.00 to $160.00 and gave the stock a &#34;market outperform&#34; rating in a report on Monday, May 4th. Eleven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $152.09.</p>
<div class="lb-trans"><p>其他一些股票分析师也对该股票发表了看法。Stifel Nicolaus 在 5 月 4 日星期一的报告中对 Celcuity 的股票设定了 150.00 美元的目标价。Guggenheim 在星期三的报告中重申了对 Celcuity 股票的 “买入” 评级。Macquarie Infrastructure 在 5 月 28 日星期四的报告中对 Celcuity 的股票设定了 160.00 美元的目标价。Leerink Partners 在星期二设定了 155.00 美元的目标价。最后，Citizens Jmp 在 5 月 4 日星期一将 Celcuity 的目标价从 150.00 美元提升至 160.00 美元，并给予该股票 “市场表现优于大盘” 的评级。共有 11 位投资分析师对该股票给予了 “买入” 评级，1 位分析师对该公司的股票给予了 “卖出” 评级。根据 MarketBeat.com 的数据，该公司目前的平均评级为 “适度买入”，目标价共识为 152.09 美元。</p>
</div><p><strong>View Our Latest Stock Analysis on Celcuity</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 Celcuity 股票分析</strong></p>
</div><h2>Celcuity Price Performance</h2>
<div class="lb-trans"><h2>Celcuity 价格表现</h2>
</div><p>CELC stock opened at $92.47 on Friday. The firm has a 50 day moving average price of $122.45 and a 200-day moving average price of $111.55. Celcuity has a 52-week low of $11.27 and a 52-week high of $151.02. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of -23.71 and a beta of 0.10. The company has a debt-to-equity ratio of 6.04, a quick ratio of 12.31 and a current ratio of 12.31.</p>
<div class="lb-trans"><p>CELC 股票在星期五开盘价为 92.47 美元。该公司的 50 日移动平均价格为 122.45 美元，200 日移动平均价格为 111.55 美元。Celcuity 的 52 周低点为 11.27 美元，52 周高点为 151.02 美元。该公司的市值为 45.1 亿美元，市盈率为-23.71，贝塔值为 0.10。该公司的债务与股本比率为 6.04，速动比率为 12.31，流动比率为 12.31。</p>
</div><h2>Institutional Investors Weigh In On Celcuity</h2>
<div class="lb-trans"><h2>机构投资者对 Celcuity 的看法</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its stake in Celcuity by 23.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,059,047 shares of the company's stock valued at $101,717,000 after buying an additional 391,262 shares during the last quarter. New York State Common Retirement Fund grew its position in shares of Celcuity by 68.0% during the 3rd quarter. New York State Common Retirement Fund now owns 47,704 shares of the company's stock valued at $2,357,000 after acquiring an additional 19,313 shares during the period. Candriam S.C.A. grew its position in shares of Celcuity by 48.3% during the 3rd quarter. Candriam S.C.A. now owns 390,924 shares of the company's stock valued at $19,312,000 after acquiring an additional 127,348 shares during the period. Choreo LLC bought a new stake in shares of Celcuity during the 3rd quarter valued at $248,000. Finally, TD Asset Management Inc bought a new stake in shares of Celcuity during the 3rd quarter valued at $3,596,000. 63.33% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>对该股票的对冲基金最近增加或减少了其持股。Vanguard Group Inc.在第三季度将其在 Celcuity 的持股增加了 23.5%。Vanguard Group Inc.现在拥有 2,059,047 股该公司的股票，价值 101,717,000 美元，此前在上个季度又购买了 391,262 股。纽约州共同退休基金在第三季度将其在 Celcuity 的持股增加了 68.0%。纽约州共同退休基金现在拥有 47,704 股该公司的股票，价值 2,357,000 美元，此前在此期间又收购了 19,313 股。Candriam S.C.A.在第三季度将其在 Celcuity 的持股增加了 48.3%。Candriam S.C.A.现在拥有 390,924 股该公司的股票，价值 19,312,000 美元，此前在此期间又收购了 127,348 股。Choreo LLC 在第三季度购买了 Celcuity 的新股份，价值 248,000 美元。最后，TD Asset Management Inc 在第三季度购买了 Celcuity 的新股份，价值 3,596,000 美元。目前 63.33% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Insiders Place Their Bets</h2>
<div class="lb-trans"><h2>内部人士下注</h2>
</div><p>In other Celcuity news, Director Richard E. Buller sold 9,000 shares of the business's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.46, for a total transaction of $1,264,140.00. Following the completion of the sale, the director directly owned 6,760 shares in the company, valued at approximately $949,509.60. The trade was a 57.11% decrease in their position. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director David Dalvey sold 25,000 shares of the business's stock in a transaction on Monday, May 4th. The shares were sold at an average price of $140.68, for a total transaction of $3,517,000.00. Following the sale, the director owned 65,000 shares of the company's stock, valued at approximately $9,144,200. This represents a 27.78% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 37,000 shares of company stock valued at $5,111,950. Company insiders own 13.33% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Celcuity 的新闻中，董事 Richard E. Buller 在 5 月 4 日星期一出售了 9,000 股该公司的股票。该股票以平均价格 140.46 美元出售，总交易额为 1,264,140.00 美元。出售完成后，该董事直接持有该公司 6,760 股股票，价值约 949,509.60 美元。此次交易使其持股减少了 57.11%。该交易已在证券交易委员会的备案中披露，相关信息可通过此链接访问。该交易是在预先安排的 10b5-1 交易计划下执行的。此外，董事 David Dalvey 在 5 月 4 日星期一出售了 25,000 股该公司的股票。该股票以平均价格 140.68 美元出售，总交易额为 3,517,000.00 美元。出售后，该董事持有 65,000 股该公司的股票，价值约 9,144,200 美元。这代表其持股减少了 27.78%。此次出售的披露信息可在 SEC 备案中找到。该交易是在预先安排的 10b5-1 交易计划下执行的。在上个季度，内部人士共出售了 37,000 股公司股票，价值 5,111,950 美元。公司内部人士持有公司股票的 13.33%。</p>
</div><h2>Key Stories Impacting Celcuity</h2>
<div class="lb-trans"><h2>影响 Celcuity 的关键故事</h2>
</div><p>Here are the key news stories impacting Celcuity this week:</p>
<div class="lb-trans"><p>以下是本周影响 Celcuity 的关键新闻故事：</p>
</div><ul>
<li>Positive Sentiment: HC Wainwright kept a <strong>Buy</strong> rating on Celcuity and reiterated a <strong>$145 price target</strong>, signaling continued analyst confidence in the company’s long-term outlook. HC Wainwright rating update</li>
<li>Positive Sentiment: Celcuity said it is <strong>expanding the Phase 3 VIKTORIA-2 trial</strong> to include <strong>endocrine-sensitive breast cancer patients</strong>, which could broaden the drug’s potential market and improve the program’s commercial opportunity. VIKTORIA-2 trial expansion</li>
<li>Positive Sentiment: Several reports highlighted <strong>strong Phase 3 breast cancer data</strong> for gedatolisib, with commentators describing the results as potentially <strong>practice-changing</strong> and supportive of a future FDA filing. Strong Phase 3 data article</li>
<li>Neutral Sentiment: HC Wainwright updated earnings estimates for fiscal 2027, including projected profitability in later quarters, but the revisions were mostly about longer-term modeling rather than an immediate business event. Analyst estimate updates</li>
<li>Negative Sentiment: Celcuity priced an <strong>upsized $500 million convertible senior note offering</strong> due 2032, up from an initially planned $400 million, raising <strong>dilution and balance-sheet concerns</strong> for shareholders. Convertible notes pricing</li>
<li>Negative Sentiment: Investors also reacted to an <strong>ASCO26 trial disappointment</strong>, with coverage noting that Celcuity was “punished” after the latest data did not fully meet market expectations. ASCO26 disappointment</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：HC Wainwright 对 Celcuity 维持 <strong>买入</strong> 评级，并重申 <strong>145 美元的目标价</strong>，显示出分析师对公司长期前景的持续信心。HC Wainwright 评级更新</li>
<li>积极情绪：Celcuity 表示正在 <strong>扩大第三阶段 VIKTORIA-2 试验</strong>，包括 <strong>内分泌敏感型乳腺癌患者</strong>，这可能会拓宽该药物的潜在市场并改善该项目的商业机会。VIKTORIA-2 试验扩展</li>
<li>积极情绪：多份报告强调了 gedatolisib 的 <strong>强劲第三阶段乳腺癌数据</strong>，评论员称这些结果可能是 <strong>改变实践的</strong>，并支持未来的 FDA 申请。强劲的第三阶段数据文章</li>
<li>中性情绪：HC Wainwright 更新了 2027 财年的盈利预测，包括后期季度的盈利能力预期，但这些修订主要是关于长期建模，而不是立即的商业事件。分析师估计更新</li>
<li>消极情绪：Celcuity 定价了一项 <strong>增大至 5 亿美元的可转换高级票据发行</strong>，到期时间为 2032 年，较最初计划的 4 亿美元有所增加，这引发了股东对 <strong>稀释和资产负债表的担忧</strong>。可转换票据定价</li>
<li>消极情绪：投资者对 <strong>ASCO26 试验失望</strong> 的反应也很强烈，报道指出，Celcuity 在最新数据未能完全满足市场预期后遭到 “惩罚”。ASCO26 失望</li>
</ul>
</div><h2>Celcuity Company Profile</h2>
<div class="lb-trans"><h2>Celcuity 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.</p>
<div class="lb-trans"><p>Celcuity, Inc 是一家临床阶段的生物技术公司，专注于精准肿瘤学诊断。该公司开发和商业化预测性生物标志物检测，旨在识别哪些患者最有可能从靶向癌症疗法中受益。通过将肿瘤细胞的功能性分析与分子分析相结合，Celcuity 力求优化治疗选择并改善实体肿瘤患者的治疗效果。</p>
</div><p>Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.</p>
<div class="lb-trans"><p>Celcuity 的专有平台使用外源性检测评估肿瘤细胞对各种治疗药物的敏感性，测量 DNA 损伤反应和其他关键通路。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Celcuity</li>
<li>Buy the Dip? Broadcom's AI Moat Is Wider Than Ever</li>
<li>The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus</li>
<li>Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand</li>
<li>Medtronic Bottoms, Healthy Rebound Ahead</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Celcuity</li>
<li>买入下跌？博通的 AI 护城河比以往更宽</li>
<li>巨大的 AI 服务器轮换将惠普企业和超微计算机置于焦点</li>
<li>Generac 的 AI 动力转型引发了关于数据中心需求的更大问题</li>
<li>美敦力触底，健康反弹在前</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9Q0VMQw" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=CELC"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Celcuity Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Celcuity 吗？</h2>
</div><p>Before you consider Celcuity, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Celcuity 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Celcuity wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Celcuity 并不在名单上。</p>
</div><p>While Celcuity currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Celcuity 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得投资。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

HC Wainwright 对 Celcuity 第三季度收益的预期为负